NEW YORK, NY / ACCESSWIRE / August 11, 2017 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.

RDI has Initiated Coverage Today on:

Cardiome Pharma Corp.
https://ub.rdinvesting.com/news/?ticker=COM-TO

Microbix Biosystems Inc.
https://ub.rdinvesting.com/news/?ticker=MBX-TO

GeneNews Limited
https://ub.rdinvesting.com/news/?ticker=GEN-TO

Essa Pharma Inc.
https://ub.rdinvesting.com/news/?ticker=EPI-TO

Cardiome Pharma Corp.'s stock moved 2.57% lower Thursday, to close the day at $4.93. The stock recorded a trading volume of 9,300 shares, which was above its three months average volume of 5,684 shares. In the last year, Cardiome Pharma Corp.'s shares have traded in a range of 3.25 - 6.06. The share price has gained 51.69% from its 52 week low. The company's shares are currently trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $5.60 is greater than its 200-day moving average of $4.70. Shares of Cardiome Pharma have gained approximately 31.47 percent year-to-date.

Access RDI's Cardiome Pharma Corp. Research Report at:
https://ub.rdinvesting.com/news/?ticker=COM-TO

On Thursday, shares in Microbix Biosystems Inc. recorded a trading volume of 16,600 shares, which was below the three months average volume of 55,738 shares. The stock ended the day flat at 0.27. The share price has gained 50.00% from its 52 week low with a 52 week trading range of 0.18 - 0.35.The company's shares are currently trading below their 200-day moving average. Moreover, the stock's 50-day moving average of $0.29 is greater than its 200-day moving average of $0.28. Shares of Microbix Biosystems have gained approximately 5.88 percent year-to-date.

Access RDI's Microbix Biosystems Inc. Research Report at:
https://ub.rdinvesting.com/news/?ticker=MBX-TO

GeneNews Limited's stock jumped 7.69% Thursday, to close the day at $0.14. The stock recorded a trading volume of 178,870 shares, which was below its three months average volume of 495,870 shares. In the last year, GeneNews Limited's shares have traded in a range of 0.13 - 0.57. The stock is currently trading 75.44% below its 52 week high. The company's shares are currently trading below their 200-day moving average. Moreover, the stock's 50-day moving average of $0.16 is below its 200-day moving average of $0.27. Shares of GeneNews have fallen approximately 54.84 percent year-to-date.

Access RDI's GeneNews Limited Research Report at:
https://ub.rdinvesting.com/news/?ticker=GEN-TO

On Thursday, shares in Essa Pharma Inc. recorded a trading volume of 49,000 shares, which was below the three months average volume of 136,623 shares. The stock ended the day 9.30% higher at 0.47. The share price has gained 51.61% from its 52 week low with a 52 week trading range of 0.31 - 4.60.The company's shares are currently trading below their 200-day moving average. Moreover, the stock's 50-day moving average of $0.56 is below its 200-day moving average of $2.22. Shares of Essa Pharma have fallen approximately 84.07 percent year-to-date.

Access RDI's Essa Pharma Inc. Research Report at:
https://ub.rdinvesting.com/news/?ticker=EPI-TO

Our Actionable Research on Cardiome Pharma Corp. (TSX:COM.TO), Microbix Biosystems Inc. (TSX:MBX.TO), GeneNews Limited (TSX:GEN.TO) and Essa Pharma Inc. (TSX:EPI.TO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com